Cingulate Stock Forum

$Cingulate (CING.US)$ Reuters· 6 mins ago
Cingulate Announces Positive Top-Line Results From High-Dose (50Mg) Fed/Fast Study of Lead Asset Ctx-1301 for Adhd

$Cingulate (CING.US)$
Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD
Tuesday, 29th April at 8:00 am
Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food
CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD
KANSAS CITY, Kan., April 29, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...

$Cingulate (CING.US)$ Press Release: Cingulate Receives $3 Million Grant From Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (Buspirone)
Dow Jones· just
Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)
CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in the $5.5 Billion U.S. Anxiety Market, and the $11.6 Billion Anxiety Mar...

$Cingulate (CING.US)$ Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301
52 SECONDS AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
KANSAS CITY, Kan., April 03, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced that it held a Pre-NDA meeting wi...

$Cingulate (CING.US)$ Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

$Cingulate (CING.US)$ Final Study Completed for Cingulate's Lead Asset CTx-1301😇

$Sharps Technology (STSS.US)$ $Verb Technology (VERB.US)$ $High Roller Technologies (ROLR.US)$ $Iveda Solutions (IVDA.US)$ $Cingulate (CING.US)$ $Star Equity (STRR.US)$ $Jowell Global (JWEL.US)$ $Cyclerion Therapeutics (CYCN.US)$ $Digital Ally (DGLY.US)$ $FOUNDER GROUP LIMITED (FGL.US)$ $Silexion Therapeutics (SLXN.US)$ $Exicure (XCUR.US)$ $Forte Biosciences (FBRX.US)$
📊⚡️📊

$Revelation Biosciences (REVB.US)$ $Nukkleus (NUKK.US)$ $Lm Funding America (LMFA.US)$ $Sonoma Pharmaceuticals (SNOA.US)$ $Vertical Aerospace (EVTL.US)$ $Advent Technologies (ADN.US)$ $Avalon Holdings (AWX.US)$ $LakeShore Biopharma (LSB.US)$ $Vicarious Surgical (RBOT.US)$ $Protagenic Therapeutics (PTIX.US)$ $Cingulate (CING.US)$ $BTC Digital (BTCT.US)$ $SemiLEDs (LEDS.US)$ $SU Group Holdings (SUGP.US)$
📊⚡️📊

$Cingulate (CING.US)$ i will keep my eyes on this one

$Cingulate (CING.US)$
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
Positive
Working capital increased by $19.5M from December 2023
Raised $12.5M in capital during Q3 2024
Net loss decreased by 46% YoY to $3.2M
R&D expenses reduced by $2.5M YoY
Secured European patents for CTx-1301 in up to 30 territories
Regained Nasdaq compliance with $1.00 minimum bid requirement
Negative
Accumulated deficit increa...